Table 1.
Preoperative and postoperative patient characteristics
| Characteristic | n = 50 |
|---|---|
| Age, median (IQR) | 70 (65-73) |
| T-Stage at RP, n (%) | |
| pT2 | 21 (42) |
| pT3a | 14 (28) |
| pT3b | 13 (26) |
| NA | 2 (4) |
| R-Stage at RP, n (%) | |
| R0 | 35 (70) |
| R+ | 9 (18) |
| Rx | 4 (8) |
| NA | 2 (4) |
| N-Stage at RP, n (%) | |
| N0 | 41 (82) |
| N+ | 7 (14) |
| Nx | 2 (4) |
| Lymph node yield at RP, median (IQR) | 14 (8-20) |
| Positive lymph nodes at RP, n (%) | |
| 0 | 41 (82) |
| 1 | 5 (10) |
| ≥2 | 2 (4) |
| Unknown | 2 (4) |
| ISUP gleason grade group at RP, n (%) | |
| I, II or III | 30 (60) |
| IV or IV | 17 (34) |
| NA | 3 (6) |
| RT after RP, n (%) | |
| Prostatic fossa | 27 (54) |
| Prostatic fossa and one/both sided pelvic lymph nodes | 6 (12) |
| Time between RP and RGS (mo), median (IQR) | 44 (23-92) |
| PSA prior to RGS (ng/mL), median (IQR) | 1.2 (0.6-3.0) |
| Surgery time (min), median (IQR) | 94 (62-139) |
| Time interval between last PSA and RGS in days, median (IQR) | 38 (6-78) |
| PSA doubling time (months), median (IQR) | 5.5 (3.2-8.8) |
| PSA velocity (ng/ml/year), median (IQR) | 1.9 (0.6-4.0) |
| PSMA-avid lesions in PET/CT, n (%) | |
| 1 | 25 (50) |
| 2 | 18 (36) |
| ≥3 | 7 (14) |
| Location of PSMA-avid lesions in PET/CT, n (%) | |
| Pelvic unilateral | 26 (52) |
| Retroperitoneal | 6 (12) |
| Pararectal/presacral | 7 (14) |
| Perivesical | 3 (6) |
| Pelvic + pararectal/perivesical | 3 (6) |
| Retroperitoneal + other | 4 (8) |
| Abdominal wall | 1 (2) |
| Highest postoperative complications (Clavien-Dindo), n (%) | |
| None | 37 (74) |
| I | 4 (8) |
| II | 1 (2) |
| IIIa | 0 |
| IIIb | 8 (16) |
| Pathologically positive lesions after RGS, n (%) | |
| 1 | 29 (58) |
| 2 | 14 (28) |
| ≥3 | 7 (14) |
| Biochemical recurrence after RGS | 31 (62) |
| Salvage therapy type after RGS | |
| None | 21 (42) |
| RT only | 3 (6) |
| ADT only | 7 (14) |
| New hormonal agent only | 2 (14) |
| ADT+ other | 10 (20) |
| Other combination | 5 (10) |
| BFS (mo) in pts. experiencing BCR during FU, median (IQR) | 6 (3-12) |
| BFS (mo) in pts. not experiencing BCR during FU, median (IQR) | 20 (13-39) |
| TFS (mo) in pts. receiving therapy during FU, median (IQR) | 7 (4-13) |
| TFS (mo) in pts. not receiving therapy during FU, median (IQR) | 19 (13-37) |
*RP: Radical prostatectomy; IQR: Interquartile range; ISUP: International Society of Urological Pathology; RT: Radiotherapy; RGS: Radioguided surgery; PSA: Prostate-specific antigen; PSMA: Prostate-specific membrane antigen; ADT: Androgen deprivation therapy; BFS: Biochemical recurrence free survival; BCR: Biochemical recurrence; TFS: Therapy free survival